Research programme - Neuroimmunological disorder therapeutics - National Institute of Neurological Disorders and Stroke/NexImmune
Latest Information Update: 21 Nov 2022
At a glance
- Originator National Institute of Neurological Disorders and Stroke; NexImmune
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Immunological disorders
Most Recent Events
- 06 Oct 2022 NexImmune enters into collaboration with National Institute of Neurological Disorders and Stroke (NINDS) for developing adoptive cell therapies for neuroimmunological disorders
- 06 Oct 2022 NexImmune has patents pending for Artificial Immune Modulation (AIM™) technology in US and multiple countries (NexImmune website, October 2022).
- 06 Oct 2022 Neximmune has patent protection for Artificial Immune Modulation (AIM™) technology in US and multiple countries (NexImmune website, October 2022).